Bavarian Nordic   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Kvistgaard Denmark (1994)

Organization Overview

First Clinical Trial
2001
NCT00189943
First Marketed Drug
1997
inactivated rabies vaccine (Imovax)
First NDA Approval
1997
inactivated rabies vaccine (Imovax)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Bavarian Nordic | Bavarian Nordic A/S | Bavarian Nordic GmbH | Bavarian Nordic, Inc.